TED-A9 is a midbrain dopaminergic progenitor cell derived from human embryonic stem cells (hESC), which can be used in the treatment of Parkinson's disease.

Premier Li Qiang presided over and approved the high-profile Implementation Plan for the Whole Chain to Support the development of Innovative Drugs.

As of June 30, 17 new stem cell drugs in China have been approved to enter clinical trials with tacit consent in 2024 (implicit approval for clinical trials), and 4 are being accepted.

The industry accelerates the layout of "cell intelligence" and enters the "fast lane".

Cell therapy will become one of the important methods of disease treatment in the future.

From January to June this year, a total of 54 companies achieved new results in the clinical application of domestic cell therapy, involving 57 cell therapy drugs.

iPSC is regarded as a revolutionary scientific discovery, which brings new hopes and opportunities for medical research and clinical application.

According to CCTV News, there are more than 400 cell and gene therapy products in clinical trials in China. Among them, there are only 100 stem cell products.